Friday, August 30, 2019 12:14:07 PM
Small Company Offering and Sale of Securities Without Registration (d)
Source: Edgar (US Regulatory)
o NoneEntity Type
0001213037
TrovaGene Inc.
XENOMICS INC
USED KAR PARTS INC
x Corporation
o Limited Partnership
o Limited Liability Company
o General Partnership
o Business Trust
o Other
Name of Issuer
Trovagene, Inc.
Jurisdiction of Incorporation/OrganizationDELAWARE Year of Incorporation/Organization xOver Five Years Ago oWithin Last Five Years (Specify Year) oYet to Be Formed
2. Principal Place of Business and Contact InformationName of Issuer Trovagene, Inc. Street Address 1Street Address 2 11055 Flintkote Avenue CityState/Province/CountryZIP/Postal CodePhone No. of Issuer San Diego CALIFORNIA 92121 858-952-7570
3. Related Persons
Last NameFirst NameMiddle NameAdamsThomasStreet Address 1Street Address 211055 Flintkote AvenueCityState/Province/CountryZIP/Postal CodeSan DiegoCALIFORNIA92121Relationship:xExecutive OfficerxDirectoroPromoterClarification of Response (if Necessary)
Last NameFirst NameMiddle NameJacobGaryStreet Address 1Street Address 211055 Flintkote AvenueCityState/Province/CountryZIP/Postal CodeSan DiegoCALIFORNIA92121Relationship:oExecutive OfficerxDirectoroPromoterClarification of Response (if Necessary)
Last NameFirst NameMiddle NameMarkinRodneyS.Street Address 1Street Address 211055 Flintkote AvenueCityState/Province/CountryZIP/Postal CodeSan DiegoCALIFORNIA92121Relationship:oExecutive OfficerxDirectoroPromoterClarification of Response (if Necessary)
Last NameFirst NameMiddle NameCountouriotisAthenaStreet Address 1Street Address 211055 Flintkote AvenueCityState/Province/CountryZIP/Postal CodeSan DiegoCALIFORNIA92121Relationship:oExecutive OfficerxDirectoroPromoterClarification of Response (if Necessary)
Last NameFirst NameMiddle NameBrancaccioJohnStreet Address 1Street Address 211055 Flintkote AvenueCityState/Province/CountryZIP/Postal CodeSan DiegoCALIFORNIA92121Relationship:oExecutive OfficerxDirectoroPromoterClarification of Response (if Necessary)
4. Industry GroupoAgriculture Health CareoRetailing Banking & Financial Services xBiotechnologyoRestaurants oCommercial Banking oHealth Insurance Technology oInsurance oHospitals & Physicians oComputers oInvesting oPharmaceuticals oTelecommunications oInvestment Banking oOther Health Care oOther Technology oPooled Investment Fund
Travel oOther Banking & Financial ServicesoManufacturing oAirlines & Airports Real Estate oLodging & Conventions oCommercial oTourism & Travel Services oConstruction oOther Travel oREITS & FinanceoOther oResidential oOther Real Estate oBusiness Services Energy oCoal Mining oElectric Utilities oEnergy Conservation oEnvironmental Services oOil & Gas oOther Energy
5. Issuer SizeRevenue RangeAggregate Net Asset Value RangeoNo RevenuesoNo Aggregate Net Asset Valueo$1 - $1,000,000o$1 - $5,000,000o$1,000,001 - $5,000,000o$5,000,001 - $25,000,000o$5,000,001 - $25,000,000o$25,000,001 - $50,000,000o$25,000,001 - $100,000,000o$50,000,001 - $100,000,000oOver $100,000,000oOver $100,000,000xDecline to DiscloseoDecline to DiscloseoNot ApplicableoNot Applicable
6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)oRule 504(b)(1) (not (i), (ii) or (iii))oRule 505oRule 504 (b)(1)(i)xRule 506(b)oRule 504 (b)(1)(ii)oRule 506(c)oRule 504 (b)(1)(iii)oSecurities Act Section 4(a)(5) oInvestment Company Act Section 3(c)
7. Type of FilingxNew NoticeDate of First Sale 2019-08-22oFirst Sale Yet to OccuroAmendment
8. Duration of OfferingDoes the Issuer intend this offering to last more than one year?oYesxNo
9. Type(s) of Securities Offered (select all that apply)oPooled Investment Fund InterestsxEquityoTenant-in-Common SecuritiesoDebtoMineral Property SecuritiesxOption, Warrant or Other Right to Acquire Another SecurityxSecurity to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire SecurityoOther (describe)
10. Business Combination TransactionIs this offering being made in connection with a business combination transaction, such as a merger, acquisition or exchange offer?oYesxNo Clarification of Response (if Necessary)
11. Minimum InvestmentMinimum investment accepted from any outside investor$ 0 USD
12. Sales Compensation
RecipientRecipient CRD NumberoNone (Associated) Broker or DealeroNone(Associated) Broker or Dealer CRD NumberoNone Street Address 1Street Address 2 CityState/Province/CountryZIP/Postal Code State(s) of SolicitationoAll States
13. Offering and Sales AmountsTotal Offering Amount$ 1500000 USDo IndefiniteTotal Amount Sold$ 1500000 USD Total Remaining to be Sold$ 0 USDo Indefinite Clarification of Response (if Necessary)
14. InvestorsoSelect if securities in the offering have been or may be sold to persons who do not qualify as accredited investors,
Number of such non-accredited investors who already have invested in the offering
Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering:1
15. Sales Commissions & Finders' Fees ExpensesProvide separately the amounts of sales commissions and finders' fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.
Sales Commissions$ 0 USDoEstimateFinders' Fees$ 0 USDoEstimate Clarification of Response (if Necessary)
16. Use of ProceedsProvide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.
$ 0 USDo
Recent CRDF News
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2024 08:06:55 PM
- Cardiff Oncology Reports Second Quarter 2024 Results and Provides Business Update • GlobeNewswire Inc. • 08/08/2024 08:05:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/08/2024 08:00:13 PM
- Cardiff Oncology to Report Second Quarter 2024 Results and Provide Business Update • GlobeNewswire Inc. • 08/01/2024 08:05:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 06/17/2024 10:10:38 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 06/03/2024 08:06:53 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/03/2024 08:03:35 PM
- Cardiff Oncology to Present at the Jefferies Healthcare Conference • GlobeNewswire Inc. • 05/29/2024 08:05:00 PM
- Cardiff Oncology to Present at Upcoming Investor Conferences in May • GlobeNewswire Inc. • 05/13/2024 08:05:00 PM
- Cardiff Oncology Reports First Quarter 2024 Results and Provides Business Update • GlobeNewswire Inc. • 05/02/2024 08:05:00 PM
- Cardiff Oncology to Report First Quarter 2024 Results and Provide Business Update • GlobeNewswire Inc. • 04/25/2024 08:05:00 PM
- Cardiff Oncology Presents Novel Preclinical Data at AACR Annual Meeting 2024 that Supports Ongoing First-line RAS-mutated mCRC Clinical Study • GlobeNewswire Inc. • 04/08/2024 08:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/07/2024 11:40:15 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/07/2024 11:40:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/07/2024 11:39:51 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/07/2024 11:39:40 PM
- Cardiff Oncology Announces Upcoming Presentations at the AACR Annual Meeting 2024 • GlobeNewswire Inc. • 03/06/2024 09:05:00 PM
- Cardiff Oncology Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update • GlobeNewswire Inc. • 02/29/2024 09:07:00 PM
- Cardiff Oncology Provides Clinical Update on Phase 2 Randomized Second-line ONSEMBLE Trial in Patients with RAS-mutated mCRC • GlobeNewswire Inc. • 02/29/2024 09:06:00 PM
- Cardiff Oncology Announces First Patient Dosed in Randomized First-line RAS-mutated Metastatic Colorectal Cancer Trial (CRDF-004) • GlobeNewswire Inc. • 02/29/2024 09:05:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/29/2024 09:00:21 PM
- Cardiff Oncology to Present at the Cowen 44th Annual Health Care Conference • GlobeNewswire Inc. • 02/26/2024 01:00:00 PM
- Cardiff Oncology to Report Fourth Quarter and Full Year 2023 Results and Provide Business Update • GlobeNewswire Inc. • 02/22/2024 01:00:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/06/2024 09:01:34 PM
- Cardiff Oncology Announces Publication of Data from Phase 1b study in second-line KRAS-mutated mCRC in Clinical Cancer Research • PR Newswire (US) • 01/17/2024 03:30:00 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM